CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD

6257.5
2.9%
Market Trading Hours* (UTC) Open now
Closes on Tuesday at 02:30

Mon - Fri: 00:00 - 02:30 03:30 - 06:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 57.0
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011013 %
Charges from full value of position ($-2.09)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011013%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011209 %
Charges from full value of position ($-2.13)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011209%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 5%
Stock exchange Japan
Commission on trade 0%

*Information provided by Capital.com

Chugai Pharmaceutical Co Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 6098.9
Open* 6199.7
1-Year Change* 82.77%
Day's Range* 6165.7 - 6275.5
52 wk Range 3,203.00-6,035.00
Average Volume (10 days) 2.40M
Average Volume (3 months) 42.73M
Market Cap 9,458.13B
P/E Ratio 27.53
Shares Outstanding 1.65B
Revenue 1,276.05B
EPS 204.59
Dividend (Yield %) 1.4202
Beta 0.92
Next Earnings Date Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 6221.6 33.0 0.53% 6188.6 6263.5 6141.8
Mar 1, 2024 6098.9 181.5 3.07% 5917.4 6121.9 5917.4
Feb 29, 2024 5959.3 85.8 1.46% 5873.5 5995.2 5861.5
Feb 28, 2024 5939.4 5.1 0.09% 5934.3 6013.2 5854.6
Feb 27, 2024 5968.3 47.9 0.81% 5920.4 6040.1 5895.4
Feb 26, 2024 5927.4 131.7 2.27% 5795.7 5952.3 5752.8
Feb 22, 2024 5608.2 -201.5 -3.47% 5809.7 5847.6 5280.0
Feb 21, 2024 5878.5 -110.7 -1.85% 5989.2 6017.2 5816.6
Feb 20, 2024 5832.6 78.8 1.37% 5753.8 5902.4 5753.8
Feb 19, 2024 5735.8 -162.6 -2.76% 5898.4 5914.4 5709.9
Feb 16, 2024 5870.5 59.8 1.03% 5810.7 5951.3 5761.8
Feb 15, 2024 5672.0 8.0 0.14% 5664.0 5710.0 5617.1
Feb 14, 2024 5618.2 -32.9 -0.58% 5651.1 5724.9 5591.2
Feb 13, 2024 5687.0 166.5 3.02% 5520.5 5715.9 5495.5
Feb 9, 2024 5426.7 -1.0 -0.02% 5427.7 5533.4 5406.7
Feb 8, 2024 5380.8 219.4 4.25% 5161.4 5402.7 5145.4
Feb 7, 2024 5152.4 80.8 1.59% 5071.6 5230.2 5040.6
Feb 6, 2024 5106.5 55.9 1.11% 5050.6 5134.4 5026.7
Feb 5, 2024 5094.5 8.0 0.16% 5086.5 5198.3 5022.7
Feb 2, 2024 5167.4 -65.8 -1.26% 5233.2 5328.9 5070.6

Chugai Pharmaceutical Co., Ltd. Events

Time (UTC) Country Event
Friday, March 29, 2024

Time (UTC)

01:00

Country

JP

Event

Chugai Pharmaceutical Co Ltd Annual Shareholders Meeting
Chugai Pharmaceutical Co Ltd Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, April 24, 2024

Time (UTC)

08:00

Country

JP

Event

Q1 2024 Chugai Pharmaceutical Co Ltd Earnings Release
Q1 2024 Chugai Pharmaceutical Co Ltd Earnings Release

Forecast

-

Previous

-

Time (UTC)

09:00

Country

JP

Event

Q1 2024 Chugai Pharmaceutical Co Ltd Earnings Call (Japanese)
Q1 2024 Chugai Pharmaceutical Co Ltd Earnings Call (Japanese)

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1259950 999759 786946 686184 579787
Revenue 1259950 999759 786946 686184 579787
Cost of Revenue, Total 476251 337680 273465 264732 262847
Gross Profit 783695 662079 513481 421452 316940
Total Operating Expense 726637 577862 485716 475587 455464
Selling/General/Admin. Expenses, Total 99872 100754 92992 100676 93416
Research & Development 148061 131276 116601 104733 99202
Unusual Expense (Income) 633 6342 953 3916
Other Operating Expenses, Total -1
Operating Income 533309 421897 301230 210597 124323
Interest Income (Expense), Net Non-Operating 769 56 -1575 519 444
Other, Net -2912 -2568 -1467 -3223 -3318
Net Income Before Taxes 531166 419385 298188 207893 121449
Net Income After Taxes 374429 302995 214733 157560 93079
Minority Interest -591
Net Income Before Extra. Items 374429 302995 214733 157560 92488
Net Income 374429 302995 214733 157560 92488
Income Available to Common Excl. Extra. Items 374429 302995 214733 157560 92488
Income Available to Common Incl. Extra. Items 374429 302995 214733 157560 92488
Diluted Net Income 374429 302995 214733 157560 92488
Diluted Weighted Average Shares 1645.34 1645.23 1645.08 1644.53 1643.76
Diluted EPS Excluding Extraordinary Items 227.57 184.166 130.53 95.8087 56.266
Dividends per Share - Common Stock Primary Issue 78 76 55 46.6662 23.9998
Diluted Normalized EPS 227.841 186.951 130.947 97.6134 56.266
Total Adjustments to Net Income
Depreciation / Amortization 1820 1810 1705 1530
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 257897 267417 312240 438496 821231
Revenue 257897 267417 312240 438496 821231
Cost of Revenue, Total 78256 91662 151329 212908 263343
Gross Profit 179641 175755 160911 225588 557888
Total Operating Expense 151209 154803 213944 289022 437396
Selling/General/Admin. Expenses, Total 27541 33264 21016 30881 69724
Research & Development 45414 44330 38216 45232 104062
Other Operating Expenses, Total -162 -14694 -1268 1 -65
Operating Income 106688 112614 98296 149474 383835
Interest Income (Expense), Net Non-Operating 788 1380 1366 -526 517
Net Income Before Taxes 107475 113994 99662 149216 381950
Net Income After Taxes 77572 83193 73501 102479 271950
Net Income Before Extra. Items 77572 83193 73501 102479 271950
Net Income 77572 83193 73501 102479 271950
Total Adjustments to Net Income 1 -1
Income Available to Common Excl. Extra. Items 77573 83193 73500 102479 271950
Income Available to Common Incl. Extra. Items 77573 83193 73500 102479 271950
Diluted Net Income 77573 83193 73500 102479 271950
Diluted Weighted Average Shares 1645.55 1645.43 1645.38 1647.18 1645.33
Diluted EPS Excluding Extraordinary Items 47.1411 50.56 44.6706 62.215 165.286
Dividends per Share - Common Stock Primary Issue 0 40 0 40 38
Diluted Normalized EPS 47.2113 50.6669 46.7553 62.215 165.43
Other, Net -1 268 -2402
Unusual Expense (Income) 160 241 4651 332
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1336540 1063660 834906 699680 600093
Cash and Short Term Investments 503107 471970 378620 338110 251597
Cash 215619 261331 205734 195514 140912
Cash & Equivalents 6550 6422 6599 8427 5948
Short Term Investments 280938 204217 166287 134169 104737
Total Receivables, Net 514283 356009 253354 181641 179559
Accounts Receivable - Trade, Net 436383 281319 195632 139628 150778
Total Inventory 292206 208838 183893 168122 159360
Prepaid Expenses 18770 17301 14997 11807 9577
Other Current Assets, Total 8171 9543 4042 0
Total Assets 1869760 1538690 1235500 1058920 919548
Property/Plant/Equipment, Total - Net 386651 352107 297490 265308 222388
Property/Plant/Equipment, Total - Gross 624847 571058 507136 459543 403954
Accumulated Depreciation, Total -238196 -218950 -209647 -194235 -181566
Intangibles, Net 25141 21974 23880 23540 22699
Other Long Term Assets, Total 109955 89176 76193 67429 64645
Total Current Liabilities 423730 327422 236070 179268 135218
Accounts Payable 144054 97203 58284 47726 35934
Accrued Expenses 65674 65074 57334 54831 48075
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 6434 6550 6649 7263 133
Other Current Liabilities, Total 207568 158595 113803 69448 51076
Total Liabilities 445371 350677 255495 204930 163683
Total Long Term Debt 7675 9490 4635 5489 82
Long Term Debt 0 0 82
Deferred Income Tax 7086 7614 9166 9304 9031
Minority Interest 664
Other Liabilities, Total 6880 6151 5624 10869 18688
Total Equity 1424390 1188020 980003 853985 755865
Common Stock 73202 73202 73202 73016 73000
Additional Paid-In Capital 68806 68223 67586 67037 66043
Retained Earnings (Accumulated Deficit) 1293350 1054050 849093 722076 618091
Unrealized Gain (Loss) -205 91 400 530 4933
Other Equity, Total -10768 -7549 -10278 -8674 -6202
Total Liabilities & Shareholders’ Equity 1869760 1538690 1235500 1058920 919548
Total Common Shares Outstanding 1645.02 1644.32 1643.87 1642.59 1641.7
Long Term Investments 11474 11776 3029 2958 9723
Capital Lease Obligations 7675 9490 4635 5489
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1256980 1272820 1226990 1336540 1184570
Cash and Short Term Investments 618765 664983 554614 503107 545295
Cash & Equivalents 331341 365016 247686 222169 274043
Short Term Investments 287424 299967 306928 280938 271252
Total Receivables, Net 317166 296993 362542 514283 275424
Accounts Receivable - Trade, Net 315625 295326 360987 512538 274658
Total Inventory 277463 266405 278859 292206 313015
Other Current Assets, Total 43585 44440 30972 26941 50833
Total Assets 1817650 1831590 1771970 1869760 1700820
Property/Plant/Equipment, Total - Net 417833 405765 399777 386651 373217
Intangibles, Net 19981 20688 19692 25141 26335
Long Term Investments 1837 1822
Other Long Term Assets, Total 122856 132316 125517 119592 114877
Total Current Liabilities 264124 298465 315151 423730 368966
Payable/Accrued 112379 97801 209835 188216
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 151745 200664 315151 147093 180750
Total Liabilities 282657 318266 335050 445371 392192
Total Long Term Debt 0 0 0 7675 0
Deferred Income Tax 4717 6750 6366 7086 6809
Other Liabilities, Total 13816 13051 13533 6880 16417
Total Equity 1534990 1513320 1436920 1424390 1308630
Common Stock 73202 73202 73202 73202 73202
Additional Paid-In Capital 69212 69112 68993 68806 68730
Retained Earnings (Accumulated Deficit) 1395690 1383920 1300730 1293350 1187850
Other Equity, Total -3109 -12915 -6004 -10973 -21158
Total Liabilities & Shareholders’ Equity 1817650 1831590 1771970 1869760 1700820
Total Common Shares Outstanding 1645.27 1645.27 1645.13 1645.02 1645.01
Accrued Expenses 60368
Current Port. of LT Debt/Capital Leases 6434
Capital Lease Obligations 7675
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Cash From Operating Activities 244112 279626 205036 206641 119074
Cash Receipts 575875 470367 340228 249500 151857
Cash Taxes Paid -152082 -104074 -66785 -34782 -31565
Changes in Working Capital -179681 -86667 -68407 -8077 -1218
Cash From Investing Activities -145994 -118927 -98312 -81741 -74060
Capital Expenditures -71239 -72866 -61411 -61177 -77671
Other Investing Cash Flow Items, Total -74755 -46061 -36901 -20564 3611
Cash From Financing Activities -145641 -107408 -99497 -66872 -35014
Financing Cash Flow Items -58 -47 -33 -2351 -981
Total Cash Dividends Paid -138220 -98644 -91442 -56370 -35010
Issuance (Retirement) of Stock, Net 236 314 410 710 977
Foreign Exchange Effects 1939 2128 1166 -947 -2215
Net Change in Cash -45584 55419 8393 57081 7785
Issuance (Retirement) of Debt, Net -7599 -9031 -8432 -8861
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities 127747 244112 271115 245927 72541
Cash Receipts 112280 575875 414162 308034 199662
Cash Taxes Paid -95596 -152082 -151090 -86223 -85484
Changes in Working Capital 111063 -179681 8043 24116 -41637
Cash From Investing Activities -35371 -145994 -123979 -76527 -33982
Capital Expenditures -27189 -71239 -59232 -50315 -36788
Other Investing Cash Flow Items, Total -8182 -74755 -64747 -26212 2806
Cash From Financing Activities -67281 -145641 -143286 -79307 -76869
Financing Cash Flow Items -15 -58 -42 -28 -15
Total Cash Dividends Paid -65366 -138220 -137798 -75741 -75160
Issuance (Retirement) of Stock, Net 120 236 225 199 146
Issuance (Retirement) of Debt, Net -2020 -7599 -5671 -3737 -1840
Foreign Exchange Effects 422 1939 2441 2465 1031
Net Change in Cash 25517 -45584 6291 92558 -37279
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
F. Hoffman La Roche, Ltd. Corporation 59.8949 1005670000 0 2023-06-30 LOW
Nomura Asset Management Co., Ltd. Investment Advisor 2.9669 49816676 -449200 2023-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.9343 32477419 0 2023-09-30 LOW
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund 1.3789 23152612 101600 2023-09-30 LOW
Daiwa Asset Management Co., Ltd. Investment Advisor 1.3492 22654053 51419 2023-09-30 LOW
SMBC Nikko Securities Inc. Research Firm 1.2673 21279000 1755000 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.0999 18467869 62900 2023-09-30 LOW
Harding Loevner LP Investment Advisor 0.9253 15535800 64400 2023-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.8873 14898116 -122400 2023-09-30 LOW
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. Investment Advisor 0.6373 10700335 8123 2023-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.5829 9787598 851234 2022-12-31 LOW
Sumitomo Life Insurance Co. Insurance Company 0.536 9000000 0 2023-06-30 LOW
BlackRock Japan Co., Ltd. Investment Advisor 0.3199 5372000 -76500 2023-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.3071 5156500 -56800 2023-09-30 LOW
California Public Employees' Retirement System Pension Fund 0.2956 4963100 -95100 2022-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.2581 4334369 1700 2023-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.2263 3799652 25617 2023-08-31 LOW
Asset Management One Co., Ltd. Investment Advisor/Hedge Fund 0.2237 3756015 27259 2023-09-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 0.2227 3738541 51900 2023-09-30 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.1997 3352605 55500 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Chugai Pharmaceutical Co., Ltd. Company profile

About Chugai Pharmaceutical Co Ltd

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.

Equity composition

FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.

Industry: Pharmaceuticals (NEC)

日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Gold

2,112.55 Price
+1.420% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0107%
Overnight fee time 22:00 (UTC)
Spread 0.29

XRP/USD

0.67 Price
+4.900% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

78.36 Price
-1.450% 1D Chg, %
Long position overnight fee 0.0260%
Short position overnight fee -0.0479%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

18,182.70 Price
-0.570% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading